Skip to main content

Physician Resources

Find a Doctor CME Refer Your Patient Medical Staff - Pineapple Connect

TPST-1120 Plus Nivolumab Offers New Treatment Potential in RCC

Metagenomic next-generation sequencing in osteoarticular infections with a focus on pediatrics: current concepts and clinical applications

TPST-1120, a first-in-class oral inhibitor of peroxisome proliferator activated receptor alpha (PPAR-alpha), appeared to be well tolerated as both monotherapy and in combination with nivolumab (Opdivo), in patients with PD-1 inhibitor-refractory cancers, including renal cell carcinoma (RCC).1



Copyright © 2023 Baptist Health South Florida. All Rights Reserved.